GOSS
Price
$0.80
Change
-$0.07 (-8.05%)
Updated
Dec 18, 04:59 PM (EDT)
92 days until earnings call
MTEM
Price
$0.36
Change
-$0.00 (-0.00%)
Updated
Dec 18, 04:59 PM (EDT)
Ad is loading...

GOSS vs MTEM

Header iconGOSS vs MTEM Comparison
Open Charts GOSS vs MTEMBanner chart's image
Gossamer Bio
Price$0.80
Change-$0.07 (-8.05%)
Volume$10.47K
CapitalizationN/A
Molecular Templates
Price$0.36
Change-$0.00 (-0.00%)
Volume$829
CapitalizationN/A
GOSS vs MTEM Comparison Chart
Loading...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MTEM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GOSS vs. MTEM commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GOSS is a Buy and MTEM is a Buy.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (GOSS: $0.87 vs. MTEM: $0.36)
Brand notoriety: GOSS and MTEM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GOSS: 70% vs. MTEM: 4%
Market capitalization -- GOSS: $197.71M vs. MTEM: $2.34M
GOSS [@Biotechnology] is valued at $197.71M. MTEM’s [@Biotechnology] market capitalization is $2.34M. The market cap for tickers in the [@Biotechnology] industry ranges from $482.1B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GOSS’s FA Score shows that 0 FA rating(s) are green whileMTEM’s FA Score has 0 green FA rating(s).

  • GOSS’s FA Score: 0 green, 5 red.
  • MTEM’s FA Score: 0 green, 5 red.
According to our system of comparison, both GOSS and MTEM are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GOSS’s TA Score shows that 4 TA indicator(s) are bullish while MTEM’s TA Score has 2 bullish TA indicator(s).

  • GOSS’s TA Score: 4 bullish, 6 bearish.
  • MTEM’s TA Score: 2 bullish, 3 bearish.
According to our system of comparison, MTEM is a better buy in the short-term than GOSS.

Price Growth

GOSS (@Biotechnology) experienced а +13.83% price change this week, while MTEM (@Biotechnology) price change was -19.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.92%, and the average quarterly price growth was +0.65%.

Reported Earning Dates

GOSS is expected to report earnings on Mar 21, 2025.

MTEM is expected to report earnings on Nov 13, 2023.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GOSS($198M) has a higher market cap than MTEM($2.34M). GOSS YTD gains are higher at: -4.384 vs. MTEM (-90.257). MTEM has higher annual earnings (EBITDA): -10.63M vs. GOSS (-52.24M). GOSS has more cash in the bank: 327M vs. MTEM (9.66M). MTEM has less debt than GOSS: MTEM (8.39M) vs GOSS (204M). GOSS has higher revenues than MTEM: GOSS (105M) vs MTEM (23.5M).
GOSSMTEMGOSS / MTEM
Capitalization198M2.34M8,447%
EBITDA-52.24M-10.63M492%
Gain YTD-4.384-90.2575%
P/E RatioN/AN/A-
Revenue105M23.5M447%
Total Cash327M9.66M3,386%
Total Debt204M8.39M2,431%
FUNDAMENTALS RATINGS
GOSS vs MTEM: Fundamental Ratings
GOSS
MTEM
OUTLOOK RATING
1..100
2827
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
39
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
4396
P/E GROWTH RATING
1..100
10045
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MTEM's Valuation (39) in the Biotechnology industry is in the same range as GOSS (43) in the Pharmaceuticals Major industry. This means that MTEM’s stock grew similarly to GOSS’s over the last 12 months.

MTEM's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as GOSS (100) in the Pharmaceuticals Major industry. This means that MTEM’s stock grew similarly to GOSS’s over the last 12 months.

GOSS's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as MTEM (100) in the Biotechnology industry. This means that GOSS’s stock grew similarly to MTEM’s over the last 12 months.

GOSS's Price Growth Rating (43) in the Pharmaceuticals Major industry is somewhat better than the same rating for MTEM (96) in the Biotechnology industry. This means that GOSS’s stock grew somewhat faster than MTEM’s over the last 12 months.

MTEM's P/E Growth Rating (45) in the Biotechnology industry is somewhat better than the same rating for GOSS (100) in the Pharmaceuticals Major industry. This means that MTEM’s stock grew somewhat faster than GOSS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GOSSMTEM
RSI
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
N/A
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
89%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 6 days ago
81%
Bullish Trend 9 days ago
80%
Declines
ODDS (%)
Bearish Trend 28 days ago
87%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
N/A
View a ticker or compare two or three
Ad is loading...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MTEM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TFOAX75.32-0.21
-0.28%
Touchstone Focused A
MSHNX13.15-0.04
-0.30%
Morgan Stanley Inst Permanence A
APDIX27.45-0.13
-0.47%
Artisan International Advisor
IBCGX21.24-0.21
-0.98%
VY® Baron Growth S2
KMDVX32.32-0.44
-1.34%
Keeley Mid Cap Dividend Value A

GOSS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GOSS has been loosely correlated with MEIP. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GOSS jumps, then MEIP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GOSS
1D Price
Change %
GOSS100%
+1.71%
MEIP - GOSS
46%
Loosely correlated
+0.78%
CGEM - GOSS
45%
Loosely correlated
-2.63%
SYRE - GOSS
41%
Loosely correlated
+3.44%
APVO - GOSS
41%
Loosely correlated
+8.25%
VIR - GOSS
41%
Loosely correlated
-2.78%
More

MTEM and

Correlation & Price change

A.I.dvisor indicates that over the last year, MTEM has been loosely correlated with GOSS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if MTEM jumps, then GOSS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MTEM
1D Price
Change %
MTEM100%
-2.44%
GOSS - MTEM
39%
Loosely correlated
+1.71%
AXON - MTEM
36%
Loosely correlated
-2.09%
CYTK - MTEM
34%
Loosely correlated
-2.53%
ASND - MTEM
32%
Poorly correlated
+2.71%
INM - MTEM
31%
Poorly correlated
N/A
More